Abstract: An implantable stent includes multiple circumferential segments that surround a bore and are connected in series along a length to form a tubular wall. Multiple adjacent alternating opposite facing crowns arranged along each segment's circumference are bridged by struts. The struts include a series of staggered arcuate edges with limited flats to provide a limited region of maximum width between significantly extended reducing diameter tapers at either end where they transition into the crowns. Connections between adjacent segments are wider and stiffer than the struts and strut-crown transitions in the segments. The crowns include inner and outer radii with off-set centers along a common axis to provide medial crown peaks along the axis that are wider than the narrowed crown shoulders on either side of the axis and from which the tapered struts extend. Material strain and flexure along the stent during lateral bending is distributed mainly within the segments, e.g.

Abstract: An implantable stent includes multiple circumferential segments that surround a bore and are connected in series along a length to form a tubular wall. Multiple adjacent alternating opposite facing crowns arranged along each segment's circumference are bridged by struts. The struts include a series of staggered arcuate edges with limited flats to provide a limited region of maximum width between significantly extended reducing diameter tapers at either end where they transition into the crowns. Connections between adjacent segments are wider and stiffer than the struts and strut-crown transitions in the segments. The crowns include inner and outer radii with off-set centers along a common axis to provide medial crown peaks along the axis that are wider than the narrowed crown shoulders on either side of the axis and from which the tapered struts extend. Material strain and flexure along the stent during lateral bending is distributed mainly within the segments, e.g.

Abstract: There is disclosed an implantable medical stent system, including: a radially expandable stent comprising a filamental structure in a pattern surrounding a bore to form a substantially tubular wall along a length relative to a longitudinal axis; in which the filamental structure includes at least one arcuate crown with a crown peak having a radius of curvature located along a reference axis, and first and second arcuate crown shoulders on first and second sides, respectively, of the reference axis; in which the filamental structure also includes at least one pair of first and second elongated struts extending from the first and second crown shoulders, respectively; the first and second elongated struts have a region of constant maximum width at an intermediate portion and tapering toward the first and second crown shoulders.

Abstract: The present disclosure relates to drug eluting devices, and their uses. The drug eluting devices can allow for perfusion during deployment. The coatings the may contain bioactive materials which elute once deployed in a patient and can have anti-proliferative, anti-inflammation, or anti-thrombotic effects. Sol gel technology can be used to coat the devices.

Abstract: The present disclosure relates to drug eluting devices, and their uses. The drug eluting devices can allow for perfusion during deployment. The coatings the may contain bioactive materials which elute once deployed in a patient and can have anti-proliferative, anti-inflammation, or anti-thrombotic effects. Sol gel technology can be used to coat the devices.

Abstract: The present disclosure relates to drug eluting devices, and their uses. The drug eluting devices can allow for perfusion during deployment. The coatings the may contain bioactive materials which elute once deployed in a patient and can have anti-proliferative, anti-inflammation, or anti-thrombotic effects. Sol gel technology can be used to coat the devices.

Abstract: An expandable, bistable open cell design incorporates the following features: a first relatively stiff portion (152) having first and second ends and a first relatively flexible portion (154) connected to the first and second ends of the first relatively stiff portion, the first relatively stiff portion and the first relatively flexible portion substantially surrounding a first open area (156) of the stent structure; a second relatively stiff portion (158) having first and second ends and a second relatively flexible portion (160) connected to the first and second ends of the first relatively stiff portion, the first relatively stiff portion and the first relatively flexible portion substantially surrounding a second open area (162) of the stent structure; and an opening (110) formed through the first relatively stiff portion and the second relatively flexible portion such that the opening connects the first and second open areas, thereby creating first and second intermediate ends (152a, 152b) of the first r

Abstract: An implantable medical stent system, including a radially expandable stent including a filamental structure in a pattern surrounding a bore to form a substantially tubular wall along a length relative to a longitudinal axis; wherein the filamental structure includes at least one actuate crown with a crown peak having a radius of curvature located along a reference axis, and first and second arcuate crown shoulders on first and second sides, respectively, of the reference axis; and wherein the filamental structure also includes at least one pair of adjacent first and second elongated struts extending from the first and second crown shoulders, respectively.

Abstract: An expandable, bistable open cell design incorporates the following features: a first relatively stiff portion (152) having first and second ends and a first relatively flexible portion (154) connected to the first and second ends of the first relatively stiff portion, the first relatively stiff portion and the first relatively flexible portion substantially surrounding a first open area (156) of the stent structure; a second relatively stiff portion (158) having first and second ends and a second relatively flexible portion (160) connected to the first and second ends of the first relatively stiff portion, the first relatively stiff portion and the first relatively flexible portion substantially surrounding a second open area (162) of the stent structure; and an opening (110) formed through the first relatively stiff portion and the second relatively flexible portion such that the opening connects the first and second open areas, thereby creating first and second intermediate ends (152a, 152b) of the first r

Abstract: An expandable, bistable open cell design incorporates the following features: a first relatively stiff portion (152) having first and second ends and a first relatively flexible portion (154) connected to the first and second ends of the first relatively stiff portion, the first relatively stiff portion and the first relatively flexible portion substantially surrounding a first open area (156) of the stent structure; a second relatively stiff portion (158) having first and second ends and a second relatively flexible portion (160) connected to the first and second ends of the first relatively stiff portion, the first relatively stiff portion and the first relatively flexible portion substantially surrounding a second open area (162) of the stent structure; and an opening (110) formed through the first relatively stiff portion and the second relatively flexible portion such that the opening connects the first and second open areas, thereby creating first and second intermediate ends (152a, 152b) of the first r

Abstract: The present disclosure relates to drug eluting devices, and their uses. The drug eluting devices can allow for perfusion during deployment. The coatings the may contain bioactive materials which elute once deployed in a patient and can have anti-proliferative, anti-inflammation, or anti-thrombotic effects. Sol gel technology can be used to coat the devices.

Abstract: Particles are provided for use in therapeutic and/or diagnostic procedures. The particles include poly[bis(trifluoroethoxy)phosphazene] and/or a derivatives thereof which may be present throughout the particles or within an outer coating of the particles. The particles can also include a core having a hydrogel formed from an acrylic-based polymer. Such particles may be provided to a user in specific selected sizes to allow for selective embolization of certain sized blood vessels or localized treatment with an active component agent in specific clinical uses. Microspheres of the present invention may further be provided with physical and/or chemical enhancements within the particles' cores to enhance visualization of the embolized tissue using a variety of medical imaging modalities, including conventional radiography, fluoroscopy, tomography, computerized tomography, ultrasound, scintillation, magnetic resonance, or other imaging technologies.

Abstract: Polymeric particles are provided for use in therapeutic and/or diagnostic procedures. The particles include poly[bis(trifluoroethoxy)phosphazene] and/or a derivatives thereof which may be present throughout the particles or within an outer coating of the particles. The particles may also include a core having a hydrogel formed from an acrylic-based polymer. Such particles may be provided to a user in specific selected sizes to allow for selective embolization of certain sized blood vessels or localized treatment with an active component agent in specific clinical uses. Particles of the present invention may further be provided as color-coded microspheres or nanospheres to allow ready identification of the sized particles in use. Such color-coded microspheres or nanospheres may further be provided in like color-coded delivery or containment devices to enhance user identification and provide visual confirmation of the use of a specifically desired size of microspheres or nanospheres.

Abstract: This disclosure relates to substrates containing at least one polyphosphazene with a forming surface as matrices for producing biological materials that can be implanted in a mammal. The disclosure also relates to a method for producing such substrates and substrates containing polyphosphazene with a micro-structured surface.

Abstract: An expandable, bistable open cell design incorporates the following features: a first relatively stiff portion (152) having first and second ends and a first relatively flexible portion (154) connected to the first and second ends of the first relatively stiff portion, the first relatively stiff portion and the first relatively flexible portion substantially surrounding a first open area (156) of the stent structure; a second relatively stiff portion (158) having first and second ends and a second relatively flexible portion (160) connected to the first and second ends of the first relatively stiff portion, the first relatively stiff portion and the first relatively flexible portion substantially surrounding a second open area (162) of the stent structure; and an opening (1 10) formed through the first relatively stiff portion and the second relatively flexible portion such that the opening connects the first and second open areas, thereby creating first and second intermediate ends (152a, 152b) of the first

Abstract: A stent is provided in combination with delivery of a tocopherol agent, and in particular a des-methyl tocopherol agent, and further beneficially a gamma-tocopherol agent, so as to reduce restenosis along the vessel or other lumenal wall where the stent is implanted. In particular applications, the stent is an endolumenal stent, and more specific beneficial applications is an endovascular stent, and the gamma-tocopherol elutes from a coating or carrier coupled with the stent. Certain combinations are provided with the des-methyl-tocopherol or phytyl substituted chromanol, e.g. gamma-tocopherol, combined with an additional agent such as an anti-restenosis agent, e.g. sirolimus, tacrolimus, everolimus, or paclitaxel, in order to provide synergistic benefit to tissues along the stented or recanalized regions. Other forms of tocopherol or tocotrienol, or other phytyl substituted chromanols, and other compounds such as palm oil, are ailso contemplated. for use to treat restenosis.

Abstract: The present invention is directed to a drug eluting stent system, including: a stent; a tocopherol agent coupled to the stent; wherein the stent is adapted to elute the tocopherol agent into a surrounding lumenal wall tissue when implanted along the lumen within a body of a patient.

Abstract: The present invention is directed to a drug eluting stent system, including: a stent; a tocopherol agent coupled to the stent; wherein the stent is adapted to elute the tocopherol agent into a surrounding lumenal wall tissue when implanted along the lumen within a body of a patient.

Abstract: The present disclosure relates to implants with a biocompatible coating having antithrombogenic properties and which also contains a pharmacologically active agent, as well as a process for their production.

Abstract: A stent is provided in combination with delivery of a tocopherol agent, and in particular a des-methyl tocopherol agent, and further beneficially a gamma-tocopherol agent, so as to reduce restenosis along the vessel or other lumenal wall where the stent is implanted. In particular applications, the stent is an endolumenal stent, and more specific beneficial applications is an endovascular stent, and the gamma-tocopherol elutes from a coating or carrier coupled with the stent. Certain combinations are provided with the des-methyl-tocopherol or phytyl substituted chromanol, e.g. gamma-tocopherol, combined with an additional agent such as an anti-restenosis agent, e.g. sirolimus, tacrolimus, everolimus, or paclitaxel, in order to provide synergistic benefit to tissues along the stented or recanalized regions. Other forms of tocopherol or tocotrienol, or other phytyl substituted chromanols, and other compounds such as palm oil, are also contemplated, for use to treat restenosis.